Home Health Care Enforcement: Total Compliance Review

January 7, 2019 Alerts and Newsletters

Both the federal Office of Inspector General and the state Attorney General's Medicaid Fraud Division have made home health care an enforcement priority. Whether it be the "face-to-face" certification requirements or third party liability clawbacks, home health agencies are at continued risk for overpayment audits, recoupments and enforcement actions. Every home health agency should identify and correct potential issues before they result in a focused audit.

Verrill Dana LLP has many years of experience representing home health agencies subject to Medicare and Medicaid audits and investigations. Working in conjunction with an experienced home care compliance professional with extensive documentation, coding and billing experience, Verrill Dana offers to review the documentation and coding processes to determine the HHA's compliance with federal and state regulatory requirements, and to offer corrective actions if necessary.

To assess the documentation flow from the initial patient referral through the various services rendered by HHA staff to the billing of those services, Verrill Dana and the compliance consultant would meet with the HHA's senior management and clinical directors. Following the initial meeting and review of the documentation and billing process, the compliance consultant would review a sample of patient files (including medical records and billing information) to assess the sufficiency of the documentation and appropriateness of the coding and billing. Thereafter, the attorneys and consultant would meet with HHA management and provide an assessment of the agency's compliance. Following that meeting, Verrill Dana would provide written recommendations regarding any issues that may need to be addressed.

Based on past legal/compliance audits conducted by Verrill Dana, it is often found that the revenue opportunities identified during the audit outweigh the costs.

Please contact Paul Shaw or another member of Verrill Dana's nationally-recognized Health Care Group if you have any questions regarding your agency's practices or would like assistance in identifying and correcting potential issues.

Firm Highlights


FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...


European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...


News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...


38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...


Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.


Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...


EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...


FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...


Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...


Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...